Trump Media and Technology Group Corp vs Novavax Inc — how do they compare? Trump Media and Technology Group Corp trades at $8.11 (market cap $2.28B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Trump Media and Technology Group Corp is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Novavax Inc for 59 Days on average.
| DJT | NVAX | |
|---|---|---|
Market Cap | $2.28B | $1.82B |
Volume | 3,148,379 | 6,198,505 |
Sector | Media | Health |
52-Week High | $17.07 | $12.56 |
52-Week Low | $7.06 | $6.22 |
Typical Hold Time | 17 Days | 59 Days |
Enterprise Value | $2.35B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.11, down 1.34% with bearish technical signals. The company reported $3.68M revenue in 2025 but a net loss of $712M, with negative margins and cash flow challenges. Recent news highlights a proposed merger with TAE Technologies and ongoing volatility linked to political developments and strategic shifts.
Outlook remains high-risk due to persistent losses and speculative sentiment. The merger with TAE offers potential diversification into fusion energy, but profitability concerns and insider selling weigh on investor confidence. Key risks include execution hurdles and dependence on political narratives.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →